US buys entire global stock of COVID-19 drug Remdesivir from Gilead


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ US buys entire global stock of COVID-19 drug Remdesivir from Gilead
US books all Remdesivir produced by Gilead Sciences leaving nothing for others

The US has secured nearly the entire world stock of antiviral drug remdesivir from US-based Gilead Sciences for the following three months, leaving hardly any stock of the important thing COVID-19 drug for the remainder of the world.

The US health department announced on Tuesday it had agreed to buy 500,000 doses for use in American hospitals.

Tests suggest remdesivir cuts recovery times, though it is not yet clear if it improves survival rates.

Gilead did sign a licensing deal in May for production outside the US but it is still in its early stages.

"President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," Department of Health and Human Services Secretary Alex Azar said in a statement.

A course of treatment in the US will cost $2,340 (£1,900). Nine companies can make the drug under license outside the US for distribution in 127 mostly poorer countries, and the cost is lower. But the project is still in its early stages.

Additional quantities are being manufactured for use in clinical trials. But critics say the US move to buy up so much stock from Gilead itself undermines international co-operation on COVID, given that other countries have taken part in trials of remdesivir, originally an anti-viral against Ebola.

"The trial that gave the result that allowed remdesivir to sell their drug wasn't just done in the US. There were patients participating through other European countries, in the UK as well, and internationally, Mexico and other places," Oxford University's Prof Peter Horby told BBC Radio 4.

He said the move also had implications for any possible future vaccine, with the need for "a much stronger framework if we are going to develop these things and they're going to be used for national emergencies".

Senior Sussex University lecturer, Ohid Yaqub, said: "It so clearly signals an unwillingness to co-operate with other countries and the chilling effect this has on international agreements about intellectual property rights."

Some in the US have criticized the purchase price, as taxpayer money had helped fund remdesivir's development.

Meanwhile back at home, the recovery rate of COVID-19 patients has improved to 59.43 percent. During the last 24 hours, 13,157 patients have been cured, taking the cumulative figure to 3,47,978. Presently, there are 2,20,114 active cases and all are under medical supervision.

As a result of the coordinated steps taken by the Central Government along with states for prevention, containment and management of COVID-19, there are 1,27,864 recovered cases more than the active COVID-19 cases, as on date.

In a statement, the Health Ministry said the testing lab network in the country is further strengthened. With 764 labs in the government sector and 292 private labs, there are as many as 1056 labs in the country.

There has been a steady rise in the number of samples tested each day. In the last 24 hours, 2,17,931 samples have been tested. The cumulative number of samples tested so far is over 88. 26 lakh.

Tags : #Remdesivir #GileadSciences #US #PresidentTrump #Covid-19 #USCovidNews #Ebola

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

No health without rights, says Shobha Shukla SDG-3 Lead Discussant at UN meetJuly 15, 2025
30 Minutes To Freedom, Robotic Surgery Ends 89-YO’s Swallowing NightmareJuly 15, 2025
Himalaya Wellness Champions Bhringaraja in New Anti-Hair Fall Campaign with a Tale of FriendshipJuly 15, 2025
ViiV Healthcare and Medicines Patent Pool extends voluntary licensing agreement to enable access to long-acting injectable HIV treatment July 15, 2025
Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025
When Weathers Go Deadly: Role Of Climate Change In Stimulating The Proliferation Of Disease-carrying VectorsJuly 14, 2025
India’s Hidden Health Emergency: Climate Pressures on WellbeingJuly 14, 2025
The Silent Urgency: Why Geriatric Health Homes Can’t Wait AnymoreJuly 14, 2025
Rewiring the Brain: How Neuroscience Apps Are Changing Stroke RecoveryJuly 14, 2025
Healing Happens at Home: How Community Care Breaks the Cycle of Repeat Hospital TripsJuly 14, 2025
The Future Is Hands-On: How AR Is Quietly Reshaping Physical TherapyJuly 14, 2025
Flying Lifelines: Why Medical Drones are Changing Supply Chains in SilenceJuly 14, 2025
The Silent Hunger Are Well Fed Indian Teens Actually MalnourishedJuly 14, 2025
Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025